The Rhythm (ASX:RHY) share price surges on cancer testing milestone

The Rhythm Biosciences Ltd (ASX: RHY) share price has opened higher on Tuesday after the successful completion of Study 6 for its ColoSTAT product. At the time of writing, the Rhythm share price is trading at $1.60, up 6.33%.

Let’s take a closer look at this announcement and what it means for the Rhythm share price.

Why the Rhythm share price opened higher on Tuesday 

The Rhythm share price has surged. Climbing from a low of 3.5 cents 12-months ago to a high of $1.675 on 2 March. The company continues to hit significant milestones. In particular, for the commercialisation of its simple, affordable, and effective ColoSTAT blood test….

Click here to view the original article.

The post The Rhythm (ASX:RHY) share price surges on cancer testing milestone appeared first on Mackay Online News.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *